Fusion Pharmaceuticals Correlations
| FUSNDelisted Stock | USD 3.75 0.33 8.09% |
A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Fusion Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Fusion Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
Fusion |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Fusion Stock performing well and Fusion Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Fusion Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| BCYC | 2.83 | (0.73) | 0.00 | 1.20 | 0.00 | 4.86 | 36.84 | |||
| RLMD | 5.92 | (2.28) | 0.00 | 3.14 | 0.00 | 6.82 | 86.20 | |||
| RAPT | 6.94 | (0.31) | 0.00 | (0.09) | 0.00 | 10.38 | 119.01 | |||
| NAMS | 3.16 | 0.43 | 0.10 | 0.58 | 3.60 | 6.54 | 46.55 | |||
| BCAB | 4.91 | (2.07) | 0.00 | (2.75) | 0.00 | 7.77 | 54.97 | |||
| PASG | 6.98 | 0.41 | 0.06 | 0.22 | 6.92 | 20.97 | 84.39 | |||
| PMVP | 1.87 | (0.24) | 0.00 | (0.53) | 0.00 | 4.35 | 12.59 | |||
| IKNA | 1.72 | (0.22) | 0.00 | (2.31) | 0.00 | 3.87 | 16.13 | |||
| OLMA | 4.59 | (1.05) | 0.00 | (0.46) | 0.00 | 7.39 | 31.66 | |||
| SPRO | 2.27 | (0.61) | 0.00 | (6.41) | 0.00 | 3.45 | 17.35 |
View Fusion Pharmaceuticals Related Equities
| Risk & Return | Correlation |
Fusion Pharmaceuticals Corporate Management
| Christopher Leamon | Chief Officer | Profile | |
| John Valliant | CEO Founder | Profile | |
| Eric Hoffman | Senior Development | Profile | |
| Dmitri MD | Chief Officer | Profile | |
| Maria Stahl | Chief Officer | Profile | |
| Victor Paulus | VP Affairs | Profile |
Still Interested in Fusion Pharmaceuticals?
Investing in delisted delisted stocks can be risky, as the stock is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.